<DOC>
	<DOCNO>NCT03093649</DOCNO>
	<brief_summary>Although patient-reported adverse event promote essential element clinical trial daily management , efficacy remain unknown . The purpose trial determine effect patient-reported adverse event treatment improvement quality life .</brief_summary>
	<brief_title>Measuring Patient-Reported Adverse Events Oncology Practice Improves Quality Life Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Patients newly histologically confirm nonkeratinizing carcinoma ( accord WHO histological type ) No evidence distant metastasis ( M0 ) Performance status : PS 0~2 Receive standard treatment Able read understand questionnaires Not exhibit overt psychopathology Willing give feedback physician write informed consent obtain WHO type keratinize squamous cell carcinoma basaloid squamous cell carcinoma . Treatment palliative intent . Prior malignancy ( except adequately treat carcinoma insitu cervix basal/squamous cell carcinoma skin ) Previous chemotherapy radiotherapy ( except nonmelanomatous skin cancer outside intend RT treatment volume ) Patient pregnant lactating Severe intercurrent disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>